The tradipitant saga stretches back to September 2024, when the FDA declined to approve Vanda’s drug in gastroparesis, a ...

Vanda is criticizing the FDA’s restrictions on information companies can provide regarding off-label use of approved ...

The potential sales revenue growth from those products is likely part of the interest in Vanda, along with the prospects for pipeline drugs. Those include tradipitant, which is under FDA review ...

Additionally, the European Medicines Agency is reviewing a marketing ... attributed to higher SG&A expenses related to commercial launches. Vanda projects 2025 revenues between $210 million ...